Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell-free DNA and the monitoring of lymphoma treatment.

Pharmacogenomics - 1 Dec 2019

Camus Vincent, Jardin Fabrice

Abstract excerpt

The technique of cell-free DNA (cfDNA) analysis, also called liquid biopsy, has been developed over the past several years to serve as a minimal residual disease tool, as has already been done with reliability and robustness in acute leukemias. This technique has important theoretical advantages, including the simplicity of acquiring blood samples, which can easily be repeated over time, its noninvasive and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Biomarkers, Tumor
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Lymphoma

Share to Mutation

Source

Identifiers

PMID: 31698998
DOI: 10.2217/pgs-2019-0099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell-free DNA and the monitoring of lymphoma treatment.PMID 31698998Read ↗

Cell-free DNA as a biomarker in cancerSemantic proximity Read ↗

Liquid biopsy in lymphoma: Molecular methods and clinical applications.Semantic proximity Read ↗

Cell-free DNA - Minimally invasive marker of hematological malignancies.Semantic proximity Read ↗

Minimal Residual Disease Using Liquid Biopsies in Hematological MalignanciesSemantic proximity Read ↗

Clinical applications of cell-free DNA-based liquid biopsy analysisSemantic proximity Read ↗

The emerging role of cell-free DNA as a molecular marker for cancer managementSemantic proximity Read ↗

Application of Cell-Free DNA Analysis to Cancer TreatmentSemantic proximity Read ↗

The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomasSemantic proximity Read ↗

Cell‐free DNA‐associated multi‐feature applications in cancer diagnosis and treatmentSemantic proximity Read ↗

Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas.Semantic proximity Read ↗

Advances in Circulating Tumor DNA Analysis.Semantic proximity Read ↗

Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.